What Is Life Expectancy With Essential Thrombocythemia?

Being diagnosed with a rare blood cancer like essential thrombocythemia (ET) is frightening, and it is entirely normal to wonder how long you will live. The reassuring news is that many people with ET have a life expectancy that is very close to that of the general population ^[1]. For many patients, ET is an indolent (slow-growing) and manageable condition rather than an immediate threat to life.

While large population studies show that average life expectancy might be slightly shorter than that of people without ET—with one study noting an average reduction of about 1.3 years over a 15-year period for older adults—many people live for decades with the condition ^[2][1].

It is important to understand that survival statistics are estimates based on large groups of people, not a personal countdown. For example, research shows that for patients diagnosed at age 40 or younger, the median survival (the time at which half the people in a study are still living) is around 35 years ^[3]. For those under 60, it is around 33 years ^[4]. Your individual outlook depends on your age, overall health, and specific risk factors.

Understanding the Primary Risks: Clotting and Bleeding

When you hear the word “cancer,” you might assume the disease itself will be the biggest threat to your longevity. With ET, the primary risks are actually cardiovascular complications—specifically thrombosis (blood clots) and, less commonly, bleeding ^[5][6].

Because ET causes your bone marrow to produce too many platelets, your blood cells can behave abnormally, increasing the risk of clots.

• Arterial thrombosis happens in the arteries and can lead to a heart attack, a stroke, or a transient ischemic attack (TIA, a temporary stroke-like episode) ^[7].
• Venous thrombosis happens in the veins, such as deep vein thrombosis (DVT) in the legs or a pulmonary embolism (PE) in the lungs ^[7].

Paradoxically, having an extremely high platelet count does not just cause clotting—it can also increase your risk of bleeding. In some cases, too many platelets can disrupt how your blood clots normally (a condition called acquired von Willebrand syndrome). This means your care team must carefully balance your risk of both clotting and bleeding.

⚠️ EMERGENCY WARNING SIGNS
Do not wait for a routine hematology appointment if you experience signs of a blood clot or severe bleeding. Call your local emergency services or go to the nearest emergency room immediately if you develop:

• Signs of a clot: Sudden numbness, weakness, or facial droop on one side of the body; trouble speaking; sudden vision loss; sudden severe headache; chest pain or pressure; sudden shortness of breath; coughing up blood; or pain, swelling, and redness in one leg.
• Signs of severe bleeding: Bleeding that will not stop with pressure; vomiting blood; black, tarry, or bloody stools; or unusually heavy bleeding.

Treatment to Protect Your Health

The primary goal of ET treatment is to prevent these dangerous clots and bleeding events ^[8]. Treatment is highly individualized based on your age, prior clot history, and genetic profile.

Some patients may be prescribed low-dose aspirin (an antiplatelet medication) to reduce clot risk, while others may need cytoreductive therapy (medications like hydroxyurea that lower the number of blood cells) ^[8][6].

Important: Never start, stop, or change your dose of aspirin or any other medication on your own. Because ET can increase both clotting and bleeding risks, aspirin is not appropriate for everyone and can be dangerous if your bleeding risk is high.

What About the Cancer Progressing?

ET is a myeloproliferative neoplasm (MPN), meaning it is a chronic blood cancer. A common fear is that it will rapidly progress to a more aggressive disease, like myelofibrosis (scarring in the bone marrow) or acute myeloid leukemia (AML).

While progression is possible, it is uncommon. In certain study cohorts, the risk of developing myelofibrosis was less than 5% within the first 10 years, and the risk of developing acute leukemia was less than 3% during that same timeframe ^[9]. Keep in mind that these are 10-year estimates, not lifetime risks, and they vary depending on individual risk factors and the specific criteria used in different studies. For most people, ET remains a stable condition requiring lifelong monitoring.

Factors That Influence Your Outlook

Your hematologist will look at several factors to determine your specific risk category and guide your treatment:

• Age and History: Being over 60 or having a history of prior blood clots significantly increases your risk for future cardiovascular events ^[10].
• Acquired Genetic Mutations: Most ET is driven by acquired genetic mutations—meaning they happen during your lifetime and are not inherited from your parents. The presence of JAK2, CALR, or MPL mutations helps doctors understand how your disease might behave. For example, JAK2 mutations are often associated with a higher risk of blood clots compared to CALR mutations ^[11].
• General Cardiovascular Health: Conditions like high blood pressure, diabetes, high cholesterol, and a history of smoking powerfully compound your risk of experiencing a dangerous blood clot ^[10][12].

Living with ET

While you cannot change your age or your genetic mutations, you have power over your cardiovascular health. Working closely with your primary care team or a cardiologist to control your blood pressure, manage diabetes, lower cholesterol, and quit smoking is one of the most effective ways to lower your overall risk of complications. While these healthy lifestyle measures cannot eliminate the risks of ET, they are a critical part of protecting your long-term health alongside your prescribed hematology treatments.